PPD Inc
NASDAQ:PPD
Intrinsic Value
PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of PPD.
PPD Inc's market capitalization is 16.6B USD.
PPD stock price is 47.28 USD.
PPD.
PPD. Open DCF Valuation
PPD. Open Relative Valuation
PPD.
PPD's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 10%.
PPD has positive Operating Income for the last twelve months.
PPD's ROIC (Return on Invested Capital) has increased in the last 3 years from 9% to 10%.
PPD's long-term liabilties (7B USD) exceed its long-term assets (7B USD).
PPD has positive three-year average ROIC (Return on Invested Capital): 8%. The company is efficient at using invested capital to generate operating income.
PPD's short-term assets (3B USD) exceed its short-term liabilties (3B USD).
PPD's Revenue has grown by an exceptional 35% over the past 12 months.
PPD has positive Free Cash Flow for the last twelve months.
PPD has positive Net Income for the last twelve months.
PPD's ROE (Return on Equity) has significantly decreased in the last 3 years from -25% to -53%, and is approaching profitability.
PPD's Altman Z-Score is equal to 1.99.
PPD has positive Gross Profit for the last twelve months.
PPD's ROE (Return on Equity) for the past 12 months is negative and is equal to -53%.
PPD has positive Net Debt. This means that the company has more debt (4B USD) than cash and short-term investments (1B USD).
PPD has negative three-year average ROE (Return on Equity): -13%. The company is not efficient at transforming stockholders' equity into net income.
PPD's D/E (Debt to Equity) is very low and is equal to -9.91.
PPD generates enough operating income (669m USD) to cover interest payments on its debt (261m USD).
Fundamental Analysis
PPD Inc
Balance Sheet Decomposition
PPD Inc
| Current Assets | 3.4B |
| Cash & Short-Term Investments | 1.2B |
| Receivables | 2.1B |
| Other Current Assets | 172.4m |
| Non-Current Assets | 3.6B |
| Long-Term Investments | 319.5m |
| PP&E | 669.4m |
| Intangibles | 619.7m |
| Other Non-Current Assets | 2B |
| Current Liabilities | 2.8B |
| Accounts Payable | 181.5m |
| Accrued Liabilities | 601.6m |
| Other Current Liabilities | 2B |
| Non-Current Liabilities | 4.7B |
| Long-Term Debt | 4.2B |
| Other Non-Current Liabilities | 446.1m |
Earnings Waterfall
PPD Inc
|
Revenue
|
5.9B
USD
|
|
Cost of Revenue
|
-3.7B
USD
|
|
Gross Profit
|
2.2B
USD
|
|
Operating Expenses
|
-1.5B
USD
|
|
Operating Income
|
669.4m
USD
|
|
Other Expenses
|
-305.4m
USD
|
|
Net Income
|
364.1m
USD
|
Free Cash Flow Analysis
PPD Inc
What is Free Cash Flow?
PPD Profitability Score
Profitability Due Diligence
PPD Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
PPD Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
PPD Solvency Score
Solvency Due Diligence
PPD Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
PPD Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PPD Price Targets Summary
PPD Inc
Company Profile
PPD Inc
Country
Industry
Market Cap
Dividend Yield
Description
PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The company is headquartered in Wilmington, North Carolina and currently employs 26,000 full-time employees. The company went IPO on 2020-02-06. The firm provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations, as well as other industry participants. The firm operates through two segments: Clinical Development Services and Laboratory Services. The Clinical Development Services segment provides a range of services to its customers including early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment provides services to its customers including bioanalytical, vaccine sciences, good manufacturing practice (GMP), central lab and biomarker testing.
You don't have any saved screeners yet
